+

WO2001081328A3 - Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose - Google Patents

Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose Download PDF

Info

Publication number
WO2001081328A3
WO2001081328A3 PCT/US2001/013131 US0113131W WO0181328A3 WO 2001081328 A3 WO2001081328 A3 WO 2001081328A3 US 0113131 W US0113131 W US 0113131W WO 0181328 A3 WO0181328 A3 WO 0181328A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
compounds
treatment
designed
metabolized
Prior art date
Application number
PCT/US2001/013131
Other languages
English (en)
Other versions
WO2001081328A2 (fr
Inventor
Pascal Druzgala
Peter G Milner
Jurg R Pfister
Original Assignee
Aryx Therapeutics
Pascal Druzgala
Peter G Milner
Jurg R Pfister
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aryx Therapeutics, Pascal Druzgala, Peter G Milner, Jurg R Pfister filed Critical Aryx Therapeutics
Priority to EP01932617A priority Critical patent/EP1276730A2/fr
Priority to CA002402123A priority patent/CA2402123A1/fr
Priority to JP2001578420A priority patent/JP2003531200A/ja
Priority to AU2001259130A priority patent/AU2001259130A1/en
Publication of WO2001081328A2 publication Critical patent/WO2001081328A2/fr
Publication of WO2001081328A3 publication Critical patent/WO2001081328A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés pharmaceutiques utiles dans le traitement du diabète de type II. Ces composés présentent un avantage étant donné qu'ils sont rapidement métabolisés par les systèmes métaboliques de détoxication. Plus particulièrement, l'invention concerne des analogues de thiazolidinedione renfermant des esters dans la structure desdits composés. L'invention se rapporte également à des méthodes de traitement de troubles tels que le diabète. Ces méthodes consistent à administrer des compositions thérapeutiquement efficaces contenant des composés pouvant être métabolisés par un sérum ou des hydrolases et estérases intracellulaires. L'invention porte enfin sur les compositions de ces analogues de thiazolidinedione contenant des esters.
PCT/US2001/013131 2000-04-24 2001-04-24 Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose WO2001081328A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01932617A EP1276730A2 (fr) 2000-04-24 2001-04-24 Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
CA002402123A CA2402123A1 (fr) 2000-04-24 2001-04-24 Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
JP2001578420A JP2003531200A (ja) 2000-04-24 2001-04-24 糖尿病、高脂血症、高コレステロール血症、およびアテローム性動脈硬化症の治療のための材料と方法
AU2001259130A AU2001259130A1 (en) 2000-04-24 2001-04-24 Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19914600P 2000-04-24 2000-04-24
US60/199,146 2000-04-24
US28198201P 2001-04-06 2001-04-06
US60/281,982 2001-04-06

Publications (2)

Publication Number Publication Date
WO2001081328A2 WO2001081328A2 (fr) 2001-11-01
WO2001081328A3 true WO2001081328A3 (fr) 2002-02-21

Family

ID=26894508

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013131 WO2001081328A2 (fr) 2000-04-24 2001-04-24 Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose

Country Status (5)

Country Link
EP (1) EP1276730A2 (fr)
JP (1) JP2003531200A (fr)
AU (1) AU2001259130A1 (fr)
CA (1) CA2402123A1 (fr)
WO (1) WO2001081328A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
EP1537068A1 (fr) 2002-07-19 2005-06-08 Aryx Therapeutics Substances et procedes pour le traitement de l'hypercholesterolemie
FR2856060A1 (fr) * 2003-06-12 2004-12-17 Centre Nat Rech Scient Groupement protecteur clivable par les albumines seriques
WO2005041951A2 (fr) * 2003-10-28 2005-05-12 Rigel Pharmaceuticals, Inc. Compositions de rhodanine utilisables comme agents antiviraux
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
CN104306373B (zh) * 2014-09-29 2017-08-08 中国科学院成都生物研究所 一种苯基恶唑类化合物在制备治疗癌症的药中的应用
TWI827583B (zh) 2018-03-08 2024-01-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528734A1 (fr) * 1991-08-20 1993-02-24 Adir Et Compagnie Dérivés de 2,4-thiazolidinedione, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0549365A1 (fr) * 1991-12-26 1993-06-30 Sankyo Company Limited Composés de thiazolidine, leur préparation et leur utilisation thérapeutique
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
WO1997032863A1 (fr) * 1996-03-08 1997-09-12 Torii Pharmaceutical Co., Ltd. Derives de thiazolidine-2,4-dione
JPH09301963A (ja) * 1996-05-17 1997-11-25 Kyorin Pharmaceut Co Ltd Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0848004A1 (fr) * 1995-07-31 1998-06-17 Shionogi & Co., Ltd. Derives de pyrrolidine possedant une activite d'inhibition de la phospholipase a2
WO2001002377A1 (fr) * 1999-07-01 2001-01-11 Geron Corporation Inhibiteurs de telomerase et leurs procedes d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528734A1 (fr) * 1991-08-20 1993-02-24 Adir Et Compagnie Dérivés de 2,4-thiazolidinedione, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0549365A1 (fr) * 1991-12-26 1993-06-30 Sankyo Company Limited Composés de thiazolidine, leur préparation et leur utilisation thérapeutique
EP0848004A1 (fr) * 1995-07-31 1998-06-17 Shionogi & Co., Ltd. Derives de pyrrolidine possedant une activite d'inhibition de la phospholipase a2
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
WO1997032863A1 (fr) * 1996-03-08 1997-09-12 Torii Pharmaceutical Co., Ltd. Derives de thiazolidine-2,4-dione
JPH09301963A (ja) * 1996-05-17 1997-11-25 Kyorin Pharmaceut Co Ltd Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO2001002377A1 (fr) * 1999-07-01 2001-01-11 Geron Corporation Inhibiteurs de telomerase et leurs procedes d'utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002181181, Database accession no. 128:13261 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002181182, Database accession no. 127:161819 *
KLETZIEN R F ET AL: "Enhancement of adipocyte differentiation by an insulin-sensitizing agent", MOLECULAR PHARMACOLOGY, vol. 41, no. 2, 1 February 1992 (1992-02-01), pages 393 - 398, XP002081233 *
SOHDA T ET AL: "Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl] thiazolidine-2,4-dione (ADD-3878) and its derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 30, no. 10, 1982, pages 3580 - 3600, XP002042079 *
UNANGST P C ET AL: "Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxy phenyl]methylene]oxazoles, -thiazoles, and -imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, no. 2, 1994, pages 322 - 328, XP002127023 *

Also Published As

Publication number Publication date
CA2402123A1 (fr) 2001-11-01
AU2001259130A1 (en) 2001-11-07
WO2001081328A2 (fr) 2001-11-01
JP2003531200A (ja) 2003-10-21
EP1276730A2 (fr) 2003-01-22

Similar Documents

Publication Publication Date Title
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
HK1061357A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
WO2003024943A3 (fr) Matieres et procedes pour le traitement de diabetes, de l'hyperlipidemie, de l'hypercholesterolemie, et de l'atherosclerose
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BG104560A (en) Long active injectable formulations containing hydrogenated castor oil
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
WO2006083779A3 (fr) Metabolites de nebivolol hydroxyles
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
LV12766A (lv) Composition of l-dopa esters
WO2005056524A3 (fr) Agents therapeutiques pour traitement de la douleur
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO2007056264A3 (fr) Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides d'une haute activite administrees par voie intraperitoneale
WO2006107411A3 (fr) Preparations ameliorees a base de fenofibrate
WO2001081328A3 (fr) Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
WO2006115770A3 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
PT1383756E (pt) Derivados de cumarina a utilizar como anticoagulantes
EP0974363A4 (fr) Remedes contre la toxicomanie
KR950000663A (ko) 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질
EP1284265A4 (fr) Derives benzothiophene et utilisation medicinale de ceux-ci
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
EP1090635A3 (fr) Utilisation de l'acide férulique pour le traitement de l'hypertension
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
WO2003026570A3 (fr) Formulations de cisplatine a toxicite reduite et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001259130

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2402123

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001932617

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 578420

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001932617

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001932617

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载